Report Overview

In 2005, the antibodies market was valued at an estimated US$14 billion, accounting for over 24 percent of the total protein therapeutics market. This share increased substantially since 2001, when it barely surpassed 13 percent. Monoclonal antibody (MAbs) therapies have been posting the fastest growth within the protein therapeutics market.

According to Arrowhead Publishers report Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline Insight the value of this market is set to reach more than $16 billion in 2006. This growth will continue in the coming years, boosted by a number of new MAbs on the market, new indications for successful medications, and their ability to treat conditions and diseases for which there is great unmet need.

Monoclonal Antibody Therapies 2007 provides an analytically-based overview of the growing market for therapeutic monoclonal antibodies, which represent the largest segment of protein-based therapeutics. An increasing number of biotech companies are investing in the MAbs field, mostly in collaboration with major pharmaceutical companies, to take advantage of this dynamic and growing field. This report assesses the overall monoclonal antibody market, as part of the wider protein therapeutics industry.

Factors influencing their historical and future performance - including manufacturing problems and the impact of future generic competition - are assessed to provide a balanced overview of the market and key products by major therapeutic categories.

Finally, the report forecasts likely revenue performance of the most successful products in the next five years, identifying key areas of growth.

Key Features of this report: